Cryptococcal Meningitis Reported With Fingolimod Treatment: Case Series.
Maurizio Del PoetaBrian J WardBenjamin GreenbergBernhard HemmerBruce A C CreeSreelatha KomatireddyJitendriya MishraRoseanne SullivanAjay KilaruAlan MooreThomas HachJoseph R BergerPublished in: Neurology(R) neuroimmunology & neuroinflammation (2022)
The causal relationship between fingolimod treatment and CM is not yet fully understood. The CM mortality rate in fingolimod-treated patients is similar to that reported in HIV-negative patients. Vigilance for signs and symptoms of CM in patients receiving fingolimod, particularly the new onset of headaches and altered mental status, is essential. Early diagnosis and treatment are critical to reducing CM-associated mortality.
Keyphrases
- multiple sclerosis
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- mental health
- cardiovascular disease
- hiv infected
- human immunodeficiency virus
- antiretroviral therapy
- depressive symptoms
- risk factors
- type diabetes
- patient reported outcomes
- smoking cessation
- combination therapy
- men who have sex with men